Date of Report (Date of earliest event reported)

March 5, 2014

NEUROKINE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia

333-161157

N/A

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1275 West 6^th Avenue, Vancouver, British Columbia, Canada

V6H 1A6

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code

(604) 805-7783

N/A

(Former name or former address, if changed since last report.)

(i)  

On March 5, 2014, Neurokine Pharmaceuticals Inc., (the “Company”) accepted the resignation of Saturna Group Chartered Accountants LLP (“Saturna Group LLP”) as the Company’s independent registered public accounting firm.

(ii)  

The reports of Saturna Group LLP on the Company’s financial statements as of and for the fiscal years ended January 31, 2013 and 2012 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle except to indicate that there was substantial doubt about the Company ability to continue as a going concern.

(iii)  

The Company’s Board of Directors participated in and approved the decision to change independent registered public accounting firms.

(v)  

The Company has requested that Saturna Group LLP furnish it with a letter addressed to the SEC stating whether or not it agrees with the above statements.  A copy of the letter provided by Saturna Group LLP is filed as Exhibit 16.1 to this Form 8-K.

(1)

On March 10, 2014 the Company engaged Sadler Gibb & Associates, LLC as its new independent registered public accounting firm.  During the two most recent fiscal years and through March 10, 2014, the Company had not consulted with Sadler Gibb & Associates, LLC regarding any of the following:

(i)

The application of accounting principles to a specific transaction, either completed or proposed;

(ii)

The type of audit opinion that might be rendered on the Company’s financial statements, and none of the following was provided to the Company:  (a) a written report, or (b) oral advice that Sadler Gibb & Associates, LLC concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issue; or

(iii)

Any matter that was subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K.